Walker Karen Marie's Form 4 filing
Kyverna Therapeutics, Inc. (KYTX) · filed Dec 17, 2025
- Accession no.
- 0001193125-25-323332
- Filed
- Dec 17, 2025
- Trade date
- Dec 15, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $292.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Walker Karen MarieCIK 0002008556 | Officer (Chief Technology Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Common Stock | MOption exerciseAcquired | +23,998 | $4.83 | +$115,910.34 | 46,634 | Direct | |
| Dec 15, 2025 | Common Stock | SSaleDisposed | −23,998 | $12.20 | −$292,775.6 | 22,636 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Common Stock | MOption exerciseDisposed | −23,998 | $0.00 | $0 | 85,865 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.